Results 71 to 80 of about 38,769 (305)

SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis

Endocrine and Metabolic Science, 2021
Background: Sleep disordered breathing (SDB) has a close association with diabetes, especially in obese patients. The use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes with SDB is a debate with conflicting evidence.
Tanveer Mir, Hassan Bin Atique, Neelambuj Regmi, Yasar Sattar, Saira Sundus, Sabah Ambreen, Prateek Lohia, Waqas T. Qureshi, Ayman Soubani   +8 more
doaj   +1 more source

Unveiling the Microvasculature: The Index of Microcirculatory Resistance and Its Expanding Role in Cardiovascular Care

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Index of microcirculatory resistance (IMR) is a cutting‐edge, wire‐based tool that advances the capability assessment of coronary microvascular function. By utilizing distal coronary pressure and mean transit time under maximal hyperemia, IMR delivers consistent, reproducible insights into the microvasculature's dynamic health.
Joanna Sohn, Matthew A. Soderstrom, Ariana Ramirez, John‐Henry Dean, Raj Shah, Debanshu Roy, Kenneth Stone, Ariel Vinas, Bryan Ramsey, Charles Lin, Robert Chilton   +10 more
wiley   +1 more source

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk

Frontiers in Pharmacology, 2019
The effect of anti-diabetic medications on bone metabolism has received increasing attention, considering that type 2 diabetes mellitus is a common metabolic disorder with adverse effects on bone metabolism.
Yangli Ye, Chenhe Zhao, Jing Liang, Yinqiu Yang, Mingxiang Yu, Xinhua Qu   +5 more
doaj   +1 more source

Investigating Cardiovascular Benefits of SGLT2 Inhibitors

, 2022
Sodium-glucose cotransporter 2 (SGLT2) inhibitors target the proximal tubule where the SGLT2 receptor is located. By blocking the receptor, glucose is forced out of the body through the urine and can no longer reabsorb into the body.
Ostroff, Jared
core  

SGLT2 Inhibitors as Potential Anticancer Agents

, 2023
Sodium-glucose cotransporter 2 (SGLT2) serves as a critical glucose transporter that has been reported to be overexpressed in cancer models, followed by increased glucose uptake in both mice and humans.
Deb, Subrata, Gamez, David, Debasish Basak, David Gamez, Subrata Deb, Basak, Debasish   +5 more
core   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?

Cardiovascular Diabetology, 2020
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF).
Atsushi Tanaka, Koichi Node
doaj   +1 more source

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know?

Tzu Chi Medical Journal
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have convincingly demonstrated efficacy in reducing cardiovascular (CV) and renal complications in patients with diabetes mellitus, chronic kidney disease, and heart failure.
Du-An Wu, Bang-Gee Hsu, Yu-Li Lin
doaj   +1 more source